Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the concentrations of interleukin‑6 (IL‑6) and tumor necrosis factor‑α (TNF‑α) were tested for in the brain tissues of AD mice.
|
29568861 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the mechanisms by which Aβ<sub>42</sub> activates the TRPM2 channel in microglial cells and the relationships to microglial activation and generation of tumor necrosis factor-α (TNF-α), a key cytokine implicated in AD.
|
29143372 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two out of 3 studies concluded that TNF-αI are beneficial in Alzheimer's disease patients, with one being an observational study and the latter being a small pilot study, with a high risk of bias.
|
29516540 |
2018 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Methods Acute hippocampal slices of male wildtype or Alzheimer's disease (AD) transgenic mouse models were treated with the inhibitors of either TNF-α, IκB Kinase (IKK) or Nuclear Factor-κB (NF-κB) in the presence or absence of oligomeric Aβ<sub>42</sub> (500 nM/2 h).
|
29458298 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report that TNF is the main inflammatory upstream mediator in choroid plexus tissue in AD patients.
|
29472246 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, AD was found to be associated with magnesium ion (Mg<sup>2+</sup>) deficit and tumor necrosis factor-alpha (TNF-α) elevation in the serum or brains of AD patients.
|
29899688 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
At 14 days after treatment, the contents of IL-1, IL-2, TNF-α and IFN-γ in blood in the stem cell treatment group were lower than those in the AD control group (P<0.05).
|
30542456 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score, MMSE score, Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) score, expression of interleukin- (IL-) 6, IL-8, and tumor necrosis factor- (TNF-) <i>α</i> in serum, and variation of blood-lipid levels were evaluated at different time points.
|
29853963 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In brain, as an endogenous stimulator, extracellular Aβ deposition activates innate immunity through binding to the pattern recognition receptors (PRR), thus leading to the production and release of substantial inflammatory mediators (NO and ROS) and cytokines (IL-1β, IL-10, IL-33 and TNF-α) contributing to the development of AD.
|
29951499 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After nine months of treatment in APP/PS1 double-transgenic mice, scutellarin significantly improves behavior, reduces soluble and insoluble Aβ levels in the brain and plasma, decreases Aβ plaque associated gliosis and levels of proinflammatory cytokines TNF-α and IL-6, attenuates neuroinflammation, displays anti-amyloidogenic effects, and highlights the beneficial effects of intervention on development or progression of AD-like neuropathology.
|
29642616 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In intra-group comparison, aMCI and mild AD with detectable levels of cytokines (TNF-α, IL-1β, IL-10, and IL-12) had decreased DMN FC.
|
29039020 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the PKC activator HMI-1a3 exerts neuroprotective functions in the in vitro models relevant for AD by reducing the production of TNFα and increasing the secretion of neuroprotective sAPPα.
|
30138694 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We evaluated OD using the Hyposmia Rating Scale (HRS), classified patients into AD with OD (AD-OD) and AD with no OD (AD-NOD) groups, and detected the levels of free radicals and inflammatory factors, including hydroxyl radical (•OH), hydrogen peroxide (H2O2), nitric oxide, interleukin-1β, interleukin-6, tumor necrosis factor-α, and prostaglandin E2 in serum from AD patients.
|
30347619 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings support the clinical development of Mcc950 and clinically available IL-1- and TNF-α-neutralizing agents in early AD.
|
29477641 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Injection of exosomes from normoxic MSCs could rescue cognition and memory impairment according to results of the Morris water maze test, reduced plaque deposition, and Aβ levels in the brain; could decrease the activation of astrocytes and microglia; could down-regulate proinflammatory cytokines (TNF-α and IL-1β); and could up-regulate anti-inflammatory cytokines (IL-4 and -10) in AD mice, as well as reduce the activation of signal transducer and activator of transcription 3 (STAT3) and NF-κB.
|
28970251 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies have reported that anti-TNF-α therapy or RA itself can modulate AD pathology, although the underlying mechanism is unclear.
|
28442538 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, selective FynT induction by TNF may facilitate persistent inflammatory responses in astrocytes, which is highly relevant to chronic neuroinflammation in neurodegenerative diseases including but not limited to AD.
|
28266558 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
It has been suggested that exogenous administration of CGRP inhibits infiltration of macrophages and expression of various inflammatory mediators such as NFkB, IL-1b, TNF-α, iNOS, matrix metalloproteinase (MMP)-9, and cell adhesion molecules like intercellular adhesion molecule (ICAM)-1 which attenuates consequence of inflammation in AD.
|
28417590 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PKR is increased in cerebrospinal fluid from patients with AD and mild cognitive impairment and can induce the activation of pro-inflammatory pathways leading to TNFα and IL1-β production.
|
28982375 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This impairment of immune functions could be mediated by: (1) the higher oxidative stress and damage also observed in blood cells from mAD and AD patients and in isolated neutrophils [lower glutathione (GSH) levels, high oxidized glutathione (GSSG)/GSH ratio, and GSSG and malondialdehyde contents], and (2) the higher release of basal pro-inflammatory cytokines (IL-6 and TNF-α) found in AD patients.
|
29375582 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease.
|
28157092 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-1β, IL-6, and TNF-α were negatively correlated to MMSE in AD patients but positively correlated to H-Y in PD patients, while HDL was positively related to H-Y in PD patients.
|
28943632 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, PLGA nanoparticles remarkably decreased the level of Aβ, reactive oxygen species (ROS), TNF-α and IL-6, and enhanced the activities of super oxide dismutase (SOD) and synapse numbers in the AD mouse brains.
|
29113362 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The mean serum resistin, IL-1<i>β</i>, IL-18, and TNF-<i>α</i> levels were significantly higher in patients with AD compared with the controls (<i>p</i>=0.026, <i>p</i>=0.002, <i>p</i>=0.003, and <i>p</i>=0.038, respectively).
|
28138112 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consistent with this, elevated systemic TNF-α is associated with more rapid cognitive decline over 6months in Alzheimer's disease patients.
|
27633985 |
2017 |